Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

Vor Biopharma Inc. (NYSE:VOR) saw some unusual options trading activity on Thursday. Investors purchased 13,899 call options on the stock. This is an increase of 11,779% compared to the typical daily volume of 117 call options.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VOR. RA Capital Management L.P. lifted its holdings in Vor Biopharma by 74.3% in the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after purchasing an additional 16,897,159 shares in the last quarter. Lynx1 Capital Management LP purchased a new position in shares of Vor Biopharma during the 4th quarter worth about $707,000. Jane Street Group LLC purchased a new position in shares of Vor Biopharma during the 1st quarter worth about $140,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Vor Biopharma during the 1st quarter worth about $100,000. Finally, Trustees of Columbia University in the City of New York purchased a new position in shares of Vor Biopharma during the 4th quarter worth about $102,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on VOR shares. Jones Trading cut shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Oppenheimer reaffirmed an “outperform” rating and set a $8.00 price target on shares of Vor Biopharma in a research note on Friday, March 21st. Baird R W cut shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Citizens Jmp cut shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 9th. Finally, JMP Securities reaffirmed a “market perform” rating and set a $6.00 price target on shares of Vor Biopharma in a research note on Friday, May 9th. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $7.06.

Vor Biopharma Trading Up 19.1%

NYSE:VOR opened at $1.06 on Friday. The firm has a market cap of $132.46 million, a price-to-earnings ratio of -0.64 and a beta of -0.51. The company’s 50-day moving average is $0.36 and its two-hundred day moving average is $0.83. Vor Biopharma has a 12-month low of $0.13 and a 12-month high of $1.80.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.